ABL1 and acute lymphoblastic leukemia: The remaining patients with Ph-like ALL have a variety of kinase alterations, including fusions involving ABL-class genes (ABL1, ABL2, CSF1R, PDGFRB, and PDGFRA) that are sensitive to ABL1 tyrosine kinase inhibitors (TKIs), rearrangements that create JAK2 fusion proteins or truncating rearrangements of the erythropoietin receptor (EPOR) that are sensitive to ruxolitinib in vitro3,4,21,27,33.